医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

joimax® Announces Partnership with Southeast Asia Distributor, Transmedic Group

2020年10月23日 AM03:07
このエントリーをはてなブックマークに追加


 

KARLSRUHE, Germany

joimax®, the German-based market leader in technologies and training methods for full-endoscopic and minimally invasive spinal surgery, is pleased to announce a new partnership with Transmedic Group, a top medical device distributor headquartered in Singapore. In this exclusive deal Transmedic will represent joimax® in Singapore, Hong Kong, Philippines and Indonesia.

The long-term partnership will provide a broader surgical choice for patients considering endoscopic minimally invasive spinal surgery in these markets. With recent advances in the field of endoscopic discectomy (ED), the procedure has potential to supersede microdiscectomy (MD) as the gold standard of care in management of lumbar disc disease, as the latest literature suggests.

“joimax® is very much looking forward to working with Transmedic Group,” says joimax® Founder and CEO Wolfgang Ries. “With the rising popularity of endoscopic approaches in the management of spinal diseases, we’re able to deliver the highest standard of patient care, strengthen our sales activities, and enter into another important partnership across APAC.”

Teo Kee Meng, managing director of Transmedic Group commented, “We’re very pleased to partner with joimax®. With their technological advancements and use of new spinal access corridors, a major prevention of spinal structure collateral damage is assured, allowing for significantly reduced complications and improved postoperative recovery times.”

About Transmedic Group

Transmedic Group was founded in 1980 with the aim of becoming the top specialist in the advanced medical technology area in Southeast Asia. Headquartered in Singapore, it has since grown its presence in seven countries with more than 500 employees, is publicly traded, and is well-renowned as the leading provider of latest technologies in healthcare.

About joimax®

Founded in Karlsruhe, Germany, in 2001, joimax® is the leading developer and marketer of complete systems for full-endoscopic and minimally invasive spinal surgery. With the Endoscopic Surgical Systems TESSYS® (transforaminal), iLESSYS® (interlaminar) and CESSYS® (cervical) for decompression procedures, MultiZYTE® for facet and sacroiliac joint pain treatment, EndoLIF® and Percusys® for minimally-invasive endoscopically assisted stabilizations, established systems are provided, addressing a whole range of indications.

In procedures for herniated disc, stenosis, pain therapy or spinal stabilization treatment, surgeons utilize joimax® technologies to operate through small incisions under local or full anesthesia, via tissue and muscle-sparing corridors and through natural openings in the spinal canal, e.g. the intervertebral foramen, the so-called “Kambin triangle”.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201022006051/en/

CONTACT

Press Contact Germany:

joimax® GmbH

Tatjana Elschnig

Tatjana.Elschnig@joimax.com

0049-721-25514-0

Press Contact USA:

joimax® Inc.

Julia Chung

Julia.Chung@joimaxusa.com

001-949-859-3472

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  •  Celltrion’s monoclonal antibody treatment for COVID-19, regdanvimab (CT-P59) becomes the first authorized COVID-19 treatment approved from the Korean Ministry of Food and Drug Safety (MFDS)
  • ENHERTU® Reduced the Risk of Disease Progression or Death by 72% Versus Trastuzumab Emtansine (T-DM1) in Patients with HER2 Positive Metastatic Breast Cancer
  • ENHERTU® Demonstrated Clinically Meaningful and Durable Response in Patients with HER2 Positive Advanced Gastric Cancer in DESTINY-Gastric02 Phase 2 Trial
  • 武田的EXKIVITY™ (mobocertinib)成为美国FDA首次核准的专为EGFR外显子20插入+ NSCLC患者设计的口服治疗药物
  • Masimo上市单例患者使用的rainbow® SuperSensor™